Ryosuke Ota

8PUBLICATIONS
15CO-AUTHORS
AutoimmunityPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursClinical pharmacology and therapeutics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Dec 21, 2025
Serious Infection Risk With TNF Inhibitors vs. JAK Inhibitors in Rheumatoid Arthritis: A Nationwide Claims-Based Cohort Study.

Ryosuke Ota, Atsushi Hirata, Takeo Hata

|Oct 31, 2024
Predictors of abemaciclib discontinuation in patients with breast cancer: a multicenter retrospective cohort study.

Noriaki Kataoka, Takeo Hata, Kouichi Hosomi

|Oct 30, 2024
Reasons and Predictors of Treatment Change in Rheumatoid Arthritis Patients Treated with Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs: A Single-Center Retrospective Observational Study.

Chihiro Nakagawa, Ryosuke Ota, Atsushi Hirata

|Jun 12, 2024
Incidence of serious infections in the working-age Japanese adult population with rheumatoid arthritis treated with tumor necrosis factor-α inhibitors and interleukin-6 inhibitors: A nationwide retrospective cohort study.

Ryosuke Ota, Atsushi Hirata, Takeo Hata

|Feb 09, 2023
Risk of infection from glucocorticoid and methotrexate interaction in patients with rheumatoid arthritis using biologics: A retrospective cohort study.

Ryosuke Ota, Takeo Hata, Atsushi Hirata

|Sep 01, 2022
Biologic Disease-Modifying and Other Anti-Rheumatic Drugs Use in Patients with Moderate-to-Severe Juvenile Idiopathic Arthritis Based on a Japanese Nationwide Claims Database.

Takeo Hata, Atsushi Hirata, Ryosuke Ota

Pageof 2

Frequent Collaborators

8 joint publications

Atsushi Hirata

6 joint publications

Takeo Hata

6 joint publications

Masami Nishihara

4 joint publications

Takahiro Katsumata